Citation: | Zhicheng GONG, Yi ZUO, Yiyang ZHONG, Shanchao ZHAO. Research status of erectile dysfunction pharmacotherapy[J]. Journal of Molecular Imaging, 2018, 41(2): 201-206. doi: 10.3969/j.issn.1674-4500.2018.02.16 |
[1] |
Feldman H, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates:results of the massachusetts male aging study[J]. J Urol, 1994(151): 54-61. https://www.researchgate.net/publication/14944126_Impotence_and_Its_Medical_and_Psychosocial_Correlates_Results_of_the_Massachusetts_Male_Aging_Study
|
[2] |
Zhang X, Yang B, Li N,et al. Risk factors for erectile dysfunction in Chinese adult males[J]. J Sex Med, 2017, 14(10): 1201-8. doi: 10.1016/j.jsxm.2017.08.009
|
[3] |
Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men[J]. J Clin Endocrinol Metab, 2007,120(92): 1245-2007.
|
[4] |
Klein R, Klein BE, Ke LE, et al. Prevalence of self-reported erectile dysfunction in People with long-term IDDM[J]. Diabetes Care, 1996, 36(19): 135-41. http://www.oalib.com/references/12043729
|
[5] |
Larsen SH, Wagner G, Heitmann BL. Sexual function and obesity[J]. Int J Obes, 2007,45(31): 1189-98. https://www.researchgate.net/publication/6433993_Sexual_function_and_obesity
|
[6] |
Mcwaine DE, Procci WR. Drug-induced sexual dysfunction[J]. Med Toxicol Adverse Drug Exp, 1988, 14(3): 289-306.
|
[7] |
Kumar RJ , Barqawi A , Crawford ED. Adverse events associated with hormonal therapy for prostate cancer[J]. Rev Urol, 2005, 7(5):37-43.
|
[8] |
Aksam A, Yassin A , Saad F. Testosterone and erectile dysfunction[J]. J Andrology, 2008, 29(4):16-23.
|
[9] |
Yassin A, Saad F. erectile D. Testosterone and erectile dysfunction[J]. J Androl, 2008, 29(6): 593-604. doi: 10.2164/jandrol.107.004630
|
[10] |
Martínez-Jabaloyas JM, Gil-Salom M, Villamón-Fort R, et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction[J]. Eur Urol, 2001, (40): 641-6.
|
[11] |
Tom F, Lue M. Physiology of penile erection and pathophysiology of erectile dysfunction[C]//Campbell-walsh urology 10th, 2011: 688-720.
|
[12] |
Morgentaler A, Goldstein I. Oral sildenafil in the treatment of erectile dysfunction[J]. J Sex Med, 2014, 11(2, SI): 117-9. http://www.jurology.com/article/S0022-5347(02)80386-X/pdf
|
[13] |
Curran M.Tadalafil[J]. Drugs, 2003, 63(11): 2203-12.
|
[14] |
Keating GM, Scott LJ. Vardenafil - A review of its use in erectile dysfunction[J]. Drugs, 2003, 63(23): 2673-703. doi: 10.2165/00003495-200363230-00010
|
[15] |
Mathers MJ, Klotz T, Brandt AS, et al. Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence[J]. BJU Int, 2008, 101(9): 1129-34. doi: 10.1111/j.1464-410X.2007.07376.x
|
[16] |
Vardi Y, Appel B, Ofer Y, et al. Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study[J]. J Urol, 2009, 182(6): 2850-5. doi: 10.1016/j.juro.2009.08.025
|
[17] |
Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk[J]. Eur Urol, 2005, 47(2): 214-20; discussion 220-2. doi: 10.1016/j.eururo.2004.10.002
|
[18] |
Santi D, Granata AR, Guidi AA, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial[J]. Eur J Endocrinol, 2016, 174(4): 513-22. doi: 10.1530/EJE-15-1100
|
[19] |
Wrishko R, Sorsaburu S, Wong DA, et al. Safety, efficacy, and pharmacokinetic overview of Low-Dose daily administration of tadalafil[J]. J Sex Med, 2009, 6(7): 2039-48. doi: 10.1111/j.1743-6109.2009.01301.x
|
[20] |
Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction[J]. Int J Impot Res, 2007, 31(19): 129-38.
|
[21] |
Angulo J, González-Corrochano R, Cuevas P, et al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries[J]. J Sex Med, 2010, 7(2 Pt 1): 758-68.
|
[22] |
Webb DJ, Gj M, Wulff M. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina[J]. J Am Coll Cardiol, 200(01): 701-5. https://www.sciencedirect.com/science/article/pii/S0735109700007051
|
[23] |
Androgens KM. Androgens and erectile function:a case for early androgen use in postprostatectomy hypogonadal men[J]. J Sex Med, 2009, 23(5): 1743-6109.
|
[24] |
Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction[J]. Clin Endocrinol (Oxf), 2000, 53(4): 517-22. doi: 10.1046/j.1365-2265.2000.01118.x
|
[25] |
Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review[J]. Ther Clin Risk Manag, 2009, 5(3): 427-48.
|
[26] |
Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists,penile erection,and sexual motivation:human studies with Melanotan II[J]. Int J Impot Res, 2000, (12): S74-9. https://www.researchgate.net/profile/Hunter_Wessells/publication/12289786_Melanocortin_receptor_agonists_penile_erection_and_sexual_motivation_Human_studies_Melanotan_II/links/54a5e9510cf257a63608d878.pdf?inViewer=0&pdfJsDownload=0&origin=publication_detail
|
[27] |
Hellstrom W, Gittelman M, Zinner N, et al. Randomized,double-blind,placebo-controlled,at-home study to evaluate the efficacy and safety of intranasal bremelanotide in men with erectile dysfunction with and without diabetes mellitus[J]. J Sex Med, 2006, 28(3): 117-25.
|
[28] |
Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: A randomized, double-blind, placebo controlled study[J]. J Urol , 2008, 179(3): 1066-71. doi: 10.1016/j.juro.2007.10.063
|
[29] |
Both S.Recent developments in Psychopharmaceutical approaches to treating female sexual interest and arousal disorder[J].Curr Sex Health Rep,2017,9(4):192-9.
|
[30] |
Cowart M, Latshaw SP, Bhatia P, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction[J]. J Med Chem, 2004, 47(15): 3853-64. doi: 10.1021/jm030505a
|
[31] |
Patel MV, Kolasa T, Mortell KA, et al. Discovery of 3-methyl-N-(1-oxy-3 `,4 `,5 `,6 `-tetrahydro-2 ` H-{[}2,4 `-bipyridine]-1 `-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D-4 agonist for the treatment of erectile dysfunction[J]. J Med Chem, 2006, 49(25): 7450-65. doi: 10.1021/jm060662k
|
[32] |
Chan JS, Kim DJ, Ahn CH, et al. Clavulanic acid stimulates sexual behaviour in male rats[J]. Eur J Pharmacol, 2009(609): 69-73. https://www.sciencedirect.com/science/article/pii/S0014299909002027
|
[33] |
Pharmaceuticals R, Inc. Efficacy study of RX-10100 to treat erectile dysfunction(ED)[EB/OL].[2009-05-05].Clinical Trials gov identifier:NCT00693056.
|
[34] |
Clinicaltrails Gov.Clinical proof-of-concept study for the combination BAY60-4552/Vardenafil for the treatment of erectile Dysfuntion not sufficiently responsive to standard therapy with PDE5 inhibitors[EB/OL].[2014-11-04].Clinical Trails gov Identifier:NCT01168817.
|
[35] |
Feldman H, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors:prospective results from the Massachusetts male aging study[J]. Prev Med, 2000,43(30): 328-38. https://www.sciencedirect.com/science/article/pii/S0091743500906431
|
[36] |
Rogers RS, Graziottin T, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats[J]. Int J Impot Res, 2003, 15(1): 26-37. doi: 10.1038/sj.ijir.3900943
|
[37] |
Dall'era JE, Meacham RB, Mills JN, et al. Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model[J]. Int J Impot Res, 2008, 20(3): 307-14. doi: 10.1038/ijir.2008.1
|
[38] |
Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia[J]. J Urol, 2003, 169(5): 1577-81. https://www.sciencedirect.com/science/article/pii/S0022534705638232
|
[39] |
Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium:deleterious effects of unregulated expression[J]. Circulation, 2000, (102): 898-901.
|
[40] |
Chae JK, Kim I, Lim ST, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization[J]. Arterioscler Thromb Vasc Biol, 2000, 20(12): 2573-8. doi: 10.1161/01.ATV.20.12.2573
|
[41] |
Ryu JK, Kim WJ, Koh YJ, et al. Designed angiopoietin-1 variant,COMP-angiopoietin-1,rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse[J]. Sci Rep, 2015, 12(5): 922-8.
|
[42] |
Jin HR, Kim WJ, Song JS, et al. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse[J]. J Sex Med, 2010, 7(11): 3635-46. doi: 10.1111/j.1743-6109.2010.01925.x
|
[43] |
Kwon MH, Ryu JK, Kim WJ, et al. Effect of intracavernous administration of angiopoietin-4 on erectile function in the Streptozotocin-Induced diabetic mouse[J]. J Sex Med, 2013, 10(12): 2912-27. doi: 10.1111/jsm.12278
|
[44] |
Kwon MH, Tuvshintur B, Kim WJ, et al. Expression of the Apelin-APJ pathway and effects on erectile function in a mouse model of vasculogenic erectile dysfunction[J]. J Sex Med, 2013, 10(12): 2928-41. doi: 10.1111/jsm.12158
|
[45] |
Bae JH, Shrestha KR, Park YH, et al. Comparison between subcutaneous injection of basic fibroblast growth Factor-Hydrogel and intracavernous injection of adipose-derived stem cells in a rat model of cavernous nerve injury[J]. Urology, 2014, 84(5): e1-7.
|
[46] |
Nishimatsu H, Suzuki E, Kumano S, et al. Adrenomedullin mediates adipose tissue-derived stem cell-induced restoration of erectile function in diabetic rats[J]. J Sex Med, 2012, 9(1): 482-93.
|
[47] |
Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats[J]. J Urol, 2005,17(3):1820-4.
|
[48] |
Chen KC, Minor TX, Rahman NU, et al. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence[J]. BJU Int, 2005, (95): 1077-80.
|
[49] |
Bakircioglu ME, Lin CS, Fan P, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence[J]. J Urol, 2001, 165(05): 66301-2. https://www.sciencedirect.com/science/article/pii/S0022534705663021
|
[50] |
Angeloni NL, Bond CW, Tang Y, et al. Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers[J]. Biomaterials, 2010, (32): 1091-101.
|
[51] |
Choe S, Veliceasa D, Bond CW, et al. Sonic hedgehog delivery from self-assembled nanofiber hydrogels reduces the fibrotic response in models of erectile dysfunction[J]. Acta Biomater, 2016, 32(32): 89-99. https://www.sciencedirect.com/science/article/pii/S1742706116300149
|
[52] |
Yin GN, Choi MJ, Kim WJ, et al. Inhibition of ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse[C]//Proceedings of the National Academy of Sciences of the United States of America, 2014: E2731-40.
|
[53] |
Burnett AL, Sezen SF, Hoke A, et al. GGF2 is neuroprotective in a rat model of cavernous nerve Injury-Induced erectile dysfunction[J]. J Sex Med, 2015, 12(4): 897-905. doi: 10.1111/jsm.12834
|
[54] |
Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury[J]. J Urol, 2004, 17(1): 495-500.
|
[55] |
Massagué J, Chen YG. Controlling TGF-beta signaling[J]. Genes Dev, 2000, (14): 627-44.
|
[56] |
Jin HR, Chung YG, Kim WJ, et al. A mouse model of cavernous nerve Injury-Induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum[J]. J Sex Med, 2010, 7(10): 3351-64. doi: 10.1111/j.1743-6109.2010.01942.x
|
[57] |
Li WJ, Xu MX, Gu M, et al. Losartan preserves erectile function by suppression of apoptosis and fibrosis of corpus cavernosum and corporal Veno-Occlusive dysfunction in diabetic rats[J]. Cell Physiol Biochem, 2017, 42(1): 333-45. doi: 10.1159/000477388
|
[58] |
Song KM, Chung JS, Choi MJ, et al. Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury[J]. J Sex Med, 2014, 11(1): 51-63. doi: 10.1111/jsm.12329
|
[59] |
Li WJ, Wang H, Zhou J, et al. P144, a TGF-beta 1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats[J]. J Sex Med, 2013, 10(12): 2942-51. doi: 10.1111/jsm.12325
|